Clinical Trials for Pancreas Cancer

A Phase I/Ib Trial of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, in Combination With Gemcitabine and Nab-paclitaxel for Advanced Pancreatic Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with stage IV pancreatic adenocarcinoma, ECOG 0–1, measurable disease, and a safely biopsiable lesion receive investigational ProAgio, an integrin αvβ3-targeting cytotoxin, with gemcitabine and nab-paclitaxel during dose escalation. Expansion cohorts evaluate ProAgio alone or with the chemotherapy combination in patients previously treated with 5-FU–based therapy.

ClinicalTrials.gov ID: NCT06182072

A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, CLDN18.2-positive adenocarcinoma of the stomach, gastroesophageal junction, esophagus, or pancreas receive AZD5863 monotherapy by intravenous or subcutaneous injection. AZD5863 is an investigational bispecific antibody that binds CLDN18.2 on tumor cells and CD3 on T cells to promote T-cell-mediated tumor killing.

ClinicalTrials.gov ID: NCT06005493

A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic pancreatic cancer who have progressed after prior chemotherapy and have ECOG performance status 0–1 receive intravenous PBP1510 (ulenistamab), an investigational antibody that neutralizes pancreatic adenocarcinoma up-regulated factor (PAUF). PBP1510 is tested alone or with gemcitabine during dose escalation, then with gemcitabine in dose expansion.

ClinicalTrials.gov ID: NCT05141149